Medication info
Empogaduo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Empogaduo Tablet 12.5/500 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samchundang Pharmaceutical Co., Ltd.
Appearance
Light brownish purple, oval film-coated tablet with a convex shape on both sides
Packaging
Inner use - 60 tablets/bottle, Inner use - 30 tablets/bottle, Inner use - 10 tablets/box [(10 tablets/PTP x 1)], Inner use - 60 tablets/box [(10 tablets/PTP x 6)]
Approval status
Active

MFDS item code 202302785 · Approved 2023.09.20 · Insurance code 651206230

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly Patients In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Samchundang Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Difficulty controlling blood sugar
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar in adult patients with type 2 diabetes. It is particularly effective for those who do not achieve adequate blood sugar control, and caution is needed when used in patients with cardiovascular disease. When taken safely under the guidance of a professional, it can assist in controlling blood sugar levels.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly Patients In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used to help control blood sugar in patients with diabetes. However, during use, there is a risk of rare complications such as severe lactic acidosis that require attention. Additionally, when taken with insulin or other antidiabetic medications, hypoglycemia may occur, so symptoms should be closely observed. This medication should not be administered to patients with moderate to severe renal impairment or acute kidney injury. Caution is also advised in conditions such as acute infections, heart failure, acute myocardial infarction, or sepsis. It is also safest for women who are pregnant or may become pregnant, as well as breastfeeding mothers, to avoid using this medication. During treatment, regular kidney function tests and careful observation of fluid status are necessary. If dehydration symptoms such as diarrhea or vomiting occur, immediate consultation with a doctor is required. Urinary or genital infections may occur, and prompt treatment should be sought if symptoms arise. This medication may lower vitamin B12 levels, necessitating regular blood tests. If surgery or tests using iodinated contrast agents are to be performed, this medication should be discontinued for a certain period, and treatment can be restarted only after confirming normal kidney function. Alcohol consumption may increase the risk of lactic acidosis, so caution should be exercised to avoid excessive drinking during therapy. Elderly patients or those at risk for fluid loss should be managed more carefully while using this medication. Any symptoms of hypoglycemia, lactic acidosis, or ketoacidosis that occur during treatment should be immediately reported to healthcare providers. Finally, its safety and efficacy have not been established in children, so its use is not recommended.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • nausea
  • vomiting
  • diarrhea
Show 180 more
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvitis
  • balanitis
  • perineal necrosis
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubal-ovarian abscess
  • vestibular neuritis
  • headache
  • sensory loss
  • positional dizziness
  • dizziness
  • drowsiness
  • asthenia
  • chest discomfort
  • chest pain
  • fatigue
  • peripheral edema
  • facial edema
  • fever
  • chills
  • unusual feelings
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive urine erythrocytes
  • ureteral stone disease
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • hyperactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • vulvar pruritus
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • obesity
  • dyslipidemia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • eye discomfort
  • conjunctival congestion
  • pathological myopia
  • retinal detachment
  • retinal calcification
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual sputum
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • tachycardia
  • arteriosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral artery occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Light brownish purple, oval film-coated tablet with a convex shape on both sides

Package unit

Inner use - 60 tablets/bottle, Inner use - 30 tablets/bottle, Inner use - 10 tablets/box [(10 tablets/PTP x 1)], Inner use - 60 tablets/box [(10 tablets/PTP x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.